Prospective Controlled Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme (GBM)- The C-GBM Study.
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2017
Price : $35 *
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms C-GBM study
- 15 Sep 2017 Status changed from active, no longer recruiting to discontinued.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 15 Aug 2016 Planned End Date changed from 1 Aug 2018 to 1 Dec 2017.